Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-04-16 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Certificate under Reg. 40(9) of SEBI(Listing Obligations and Disclosure Requirements), Regulations, 2015 for the half year ended at March 31, 2021.
Regulatory Filings
2021-04-16 English
Half yearly certificate under Reg 7(3) of LODR as on March 31, 2021.
Regulatory Filings
2021-04-09 English
Acquisition
M&A Activity Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (National Stock Exchange of India Ltd. and BSE Ltd.) under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the acquisition of 100% ownership interest in Pharmarack Technologies Private Limited by DigiHealth Technologies LLP, a wholly owned entity of an investee entity. The document includes detailed information about the acquisition such as the name of the target entity, industry, nature of consideration, cost of acquisition, percentage of shareholding acquired, and background of the acquired entity. This type of disclosure is typical for announcements related to mergers, acquisitions, or takeover bids. It is not a full financial report, audit report, or earnings release, nor is it a regulatory filing or certification. The document is not a proxy solicitation, voting result, or remuneration report. Given the content and context, the document fits best under the category of M&A Activity (TAR). The document length (6333 characters) and detailed annexure support this classification with high confidence.
2021-04-01 English
Lupin Limited has informed the Exchange about Acquisition.
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure letter addressed to the National Stock Exchange of India Ltd. and BSE Ltd. It references compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to continuous disclosure obligations for listed companies. The content details an acquisition transaction where a wholly owned entity of the investee company is acquiring 100% ownership interest in another company, Pharmarack Technologies Private Limited. The document includes specifics such as the nature of the acquisition, consideration, cost, percentage acquired, and background of the target entity. This is a clear announcement of a merger/acquisition activity rather than a full merger filing or tender offer document. It is not a financial report, earnings release, or management discussion. The document length is 6324 characters, which is sufficient for a detailed announcement but does not constitute a full report. Therefore, the appropriate classification is "Capital/Financing Update (CAP)" as it relates to company financing and acquisition activities disclosed under regulatory requirements.
2021-04-01 English
Lupin Limited has informed the Exchange about Acquisition.
Regulatory Filings
2021-03-31 English
Acquisition
M&A Activity Classification · 95% confidence The document text primarily discusses the acquisition of a target entity, including details about the target companies, the nature of the acquisition, shareholding percentages, cost of acquisition, and timelines. It includes specific information about the business, ownership, and transaction terms. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. The content is focused on a transaction involving acquisition, which fits the category of M&A Activity filings. The document length is under 5,000 characters but contains substantive details about the acquisition rather than just an announcement or a link to a report, so it is not a Report Publication Announcement. Therefore, the most appropriate classification is M&A Activity (TAR).
2021-03-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.